Mobile

A Six-Week, multicenter, randomized, double-masked study to evaluate the efficacy and safety of dosing once-daily Travoprost/Timolol in the morning vs. twice-daily Dorzolamide/Timolol in patients with...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004767-34

A Six-Week, multicenter, randomized, double-masked study to evaluate the efficacy and safety of dosing once-daily Travoprost/Timolol in the morning vs. twice-daily Dorzolamide/Timolol in patients with open-angle glaucoma or ocular hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the IOP-lowering efficacy and safety of dosing of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution (once-daily morning dosing) vs. Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution, dosed twice-daily, in patients with open-angle glaucoma or ocular hypertension.

Critère d'inclusion

  • Open-angle glaucoma and ocular hypertension

Liens